A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials.
Journal
Npj mental health research
ISSN: 2731-4251
Titre abrégé: Npj Ment Health Res
Pays: England
ID NLM: 9918592488906676
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
22
12
2023
accepted:
16
04
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
Pre-prohibition psychedelic research with complex psychiatric patients generated a wealth of treatment methodologies and practices, providing invaluable clinical insights pertaining to the medical administration of psychedelics in various mental health diagnoses. Building upon these early studies, which lack the rigor and research tools available today, contemporary psychedelic research has focused on investigating the safety and efficacy of psychedelics in randomized controlled trials via psychometric measures and symptom assessments. Both then and now, the treatment context and the role of clinicians in psychedelic treatment has been recognized as an essential feature for positive patient outcomes. To broaden the knowledge base of modern psychedelic research and support the training of clinicians conducting medically supervised psychedelic research studies, this paper provides a review of pre-prohibition clinical research narratives pertaining to the phenomenology of psychedelic treatment and the role of the non-pharmacological treatment factors in the patient experience. Lastly, this paper explores a range of clinician perspectives and psychological interventions employed in pre-prohibition psychedelic research to inform future research directions and best practice guidelines.
Identifiants
pubmed: 38956330
doi: 10.1038/s44184-024-00068-9
pii: 10.1038/s44184-024-00068-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
33Informations de copyright
© 2024. The Author(s).
Références
Greenway, K. T., Garel, N., Jerome, L. & Feduccia, A. A. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments. Expert Rev. Clin. Pharmacol. 13, 655–670 (2020).
pubmed: 32478631
doi: 10.1080/17512433.2020.1772054
Hofmann, A. LSD: My Problem Child (Oxford University Press, 2013).
Rucker, J. J. H., Iliff, J. & Nutt, D. J. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology 142, 200–218 (2018).
pubmed: 29284138
doi: 10.1016/j.neuropharm.2017.12.040
Rucker, J. J. & Seth, P. Psychedelics: old drugs, new trips. J. Psychopharmacol. 35, 316–318 (2021).
pubmed: 33853423
doi: 10.1177/02698811211003495
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C. & Mento, C. Psychedelic-assisted psychotherapy—a systematic review of associated psychological interventions. Front. Psychol. 13, 887255 (2022).
pubmed: 35756295
pmcid: 9226617
doi: 10.3389/fpsyg.2022.887255
Passie, T., Guss, J. & Krähenmann, R. Lower-dose psycholytic therapy - a neglected approach. Front. Psychiatry 13, 1020505 (2022).
pubmed: 36532196
pmcid: 9755513
doi: 10.3389/fpsyt.2022.1020505
Abramson, H. A. Lysergic acid diethylamide (LSD-25): XIX. As an adjunct to brief psychotherapy, with special reference to ego enhancement. J. Psychol. 41, 199–229 (1956).
doi: 10.1080/00223980.1956.9916216
Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D. & Young, A. H. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J. Psychopharmacol. 30, 1220–1229 (2016).
pubmed: 27856684
doi: 10.1177/0269881116679368
Lewis, D. J. & Sloane, R. B. Therapy with lysergic acid diethylamide. J. Clin. Exp. Psychopathol. 19, 19–31 (1958).
pubmed: 13525450
Jensen, S. E. A treatment program for alcoholics in a mental hospital. Q. J. Stud. Alcohol 23, 315–320 (1962).
pubmed: 14451676
doi: 10.15288/qjsa.1962.23.315
Chandler, A. L. & Hartman, M. A. Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. AMA Arch. Gen. Psychiatry 2, 286–299 (1960).
doi: 10.1001/archpsyc.1960.03590090042008
Mogar, R. E. & Savage, C. Personality change associated with psychedelic (LSD) therapy: a preliminary report. Psychother. Theory Res. Pract. 1, 154 (1964).
doi: 10.1037/h0088594
Ditman, K. S. et al. Dimensions of the LSD, methylphenidate and chlordiazepoxide experiences. Psychopharmacologia 14, 1–11 (1969).
pubmed: 4900730
doi: 10.1007/BF00401528
Stockings, G. T. A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenic and other psychotic states. J. Ment. Sci. 86, 29–47 (1940).
doi: 10.1192/bjp.86.360.29
Waltz, M. Autism: A Social and Medical History. p. 83-98 (Springer, 2023).
Griffiths, R. R. et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218, 649–665 (2011).
pubmed: 21674151
pmcid: 3308357
doi: 10.1007/s00213-011-2358-5
Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264–355 (2016).
pubmed: 26841800
pmcid: 4813425
doi: 10.1124/pr.115.011478
Grof, S. Address to the Conference of the European Association for Psycholytic Therapy (1969).
Aaronson, B., and Osmond, H. Psychedelics: The Uses And Implications Of Hallucinogenic Drugs (Doubleday, 1970).
Barral, M. R. The varieties of psychedelic experience. Int. Philos. Q. 7, 677–680 (1967).
doi: 10.5840/ipq19677433
Chwelos, N., Blewett, D. B., Smith, C. M. & Hoffer, A. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Q. J. Stud. Alcohol 20, 577–590 (1959).
pubmed: 13810249
doi: 10.15288/qjsa.1959.20.577
Sherwood, J. N., Stolaroff, M. J. & Harman, W. W. The psychedelic experience-a new concept in psychotherapy. J. Psychedelic Drugs 1, 96–111 (1968).
doi: 10.1080/02791072.1968.10524522
Eisner, B. Set, setting, and matrix. J. Psychoactive Drugs 29, 213–216 (1997).
pubmed: 9250949
doi: 10.1080/02791072.1997.10400190
Sandison, R. A. Psychological aspects of the LSD treatment of the neuroses. J. Ment. Sci. 100, 508–515 (1954).
pubmed: 13175012
doi: 10.1192/bjp.100.419.508
Sandison, R. A., Spencer, A. M. & Whitelaw, J. D. A. The therapeutic value of lysergic acid diethylamide in mental illness. J. Ment. Sci. 100, 491–507 (1954).
pubmed: 13175011
doi: 10.1192/bjp.100.419.491
Hartogsohn, I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J. Psychopharmacol. 30, 1259–1267 (2016).
pubmed: 27852960
doi: 10.1177/0269881116677852
Carhart-Harris, R. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399–408 (2018).
pubmed: 29119217
doi: 10.1007/s00213-017-4771-x
Hartogsohn, I. Constructing drug effects: a history of set and setting. Drug Sci. Policy Law 3, 2050324516683325 (2017).
doi: 10.1177/2050324516683325
Leary, T., Litwin, G. H. & Metzner, R. Reactions to psilocybjn administered in a supportive environment. J. Nerv. Ment. Dis. 137, 561–573 (1963).
pubmed: 14087676
doi: 10.1097/00005053-196312000-00007
Alnæs, R. THERAPEUTIC APPLICATION OF THE CHANGE IN CONSCIOUSNESS PRODUCED RY PSYCHOLYTICA (LSD, PSILOCYRIN, ETC.) 1: the psychedelic experience in the treatment of neurosis. Acta Psychiatr. Scand. 39, 397–409 (1964).
pubmed: 14345225
doi: 10.1111/j.1600-0447.1964.tb04952.x
Whitaker, L. H. Lysergic acid diethylamide in psychotherapy. Part I: clinical aspects. Med. J. Aust. 1, 5–8 (1964).
pubmed: 14116718
doi: 10.5694/j.1326-5377.1964.tb133752.x
Smith, C. M. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. Q. J. Stud. Alcohol 19, 406–417 (1958).
pubmed: 13579169
doi: 10.15288/qjsa.1958.19.406
Yaden, D. B., Yaden, M. E. & Griffiths, R. R. Psychedelics in psychiatry-keeping the renaissance from going off the rails. JAMA Psychiatry 78, 469–470 (2021).
pubmed: 33263720
pmcid: 8102315
doi: 10.1001/jamapsychiatry.2020.3672
Mitchell, J. M. & Anderson, B. T. Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology 49, 96–103 (2024).
pubmed: 37479859
doi: 10.1038/s41386-023-01656-7
Modlin, N. L., Stubley, J., Maggio, C. & Rucker, J. J. On redescribing the indescribable: trauma, psychoanalysis and psychedelic therapy. Br. J. Psychother. 39, 551–572 (2023).
doi: 10.1111/bjp.12852
Carhart-Harris, R. L. How do psychedelics work. Curr. Opin. Psychiatry 32, 16–21 (2019).
pubmed: 30394903
doi: 10.1097/YCO.0000000000000467
Nayak, S. M., Singh, M., Yaden, D. B. & Griffiths, R. R. Belief changes associated with psychedelic use. J. Psychopharmacol. 37, 80–92 (2023).
pubmed: 36317643
doi: 10.1177/02698811221131989
Roseman, L. et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J. Psychopharmacol. 33, 1076–1087 (2019).
pubmed: 31294673
doi: 10.1177/0269881119855974
Peill, J. M. et al. Validation of the Psychological Insight Scale: a new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36, 31–45 (2022).
pubmed: 34983255
pmcid: 8801624
doi: 10.1177/02698811211066709
Brennan, W., Kelman, A. R. & Belser, A. B. A systematic review of reporting practices in psychedelic clinical trials: psychological support, therapy, and psychosocial interventions. Psychedelic Med. 1, 218–229 (2023).
doi: 10.1089/psymed.2023.0007
Ko, K., Kopra, E. I., Cleare, A. J. & Rucker, J. J. Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J. Affect Disord. 322, 194–204 (2023).
pubmed: 36209780
doi: 10.1016/j.jad.2022.09.168
Mitchell, J. M. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat. Med. 29, 2473–2480 (2023).
pubmed: 37709999
pmcid: 10579091
doi: 10.1038/s41591-023-02565-4
van Elk, M. & Fried, E. I. History repeating: guidelines to address common problems in psychedelic science. Ther. Adv. Psychopharmacol. 13, 20451253231198466 (2023).
pubmed: 37766730
pmcid: 10521293
doi: 10.1177/20451253231198466
Kisely, S. The down-scheduling of MDMA and psilocybin(e): too fast and too soon. Aust. N. Z. J. Psychiatry 57, 933–934 (2023).
pubmed: 37161273
pmcid: 10291367
doi: 10.1177/00048674231174171
Busch, A. K. & Johnson, W. C. LSD 25 as an aid in psychotherapy; preliminary report of a new drug. Dis. Nerv. Syst. 11, 241–243 (1950).
pubmed: 14793387
Eisner, B. G. & Cohen, S. Psychotherapy with lysergic acid diethylamide. J. Nerv. Ment. Dis. 127, 528–539 (1958).
pubmed: 13621221
doi: 10.1097/00005053-195812000-00006
Rolo, A., Krinsky, L. W. & Goldfarb, L. LSD as an adjunct to psychotherapy with alcoholics. J. Psychol. 50, 85–104 (1960).
doi: 10.1080/00223980.1960.9916425
Johnson, F. G. LSD in the treatment of alcoholism. Am. J. Psychiatry 126, 481–487 (1969).
pubmed: 5806791
doi: 10.1176/ajp.126.4.481
Pahnke, W. N. & Richards, W. A. Implications of LSD and experimental mysticism. J. Relig. Health 5, 175–208 (1966).
pubmed: 24424798
doi: 10.1007/BF01532646
Preller, K. H. & Vollenweider, F. X. Phenomenology, structure, and dynamic of psychedelic states. Curr. Top. Behav. Neurosci. 36, 221–256 (2018).
pubmed: 28025814
doi: 10.1007/7854_2016_459
Graziosi, M., Singh, M., Nayak, S. M. & Yaden, D. B. Acute subjective effects of psychedelics within and beyond WEIRD contexts. J. Psychoact. Drugs 55, 558–569 (2023).
doi: 10.1080/02791072.2023.2255274
Osmond, H. A review of the clinical effects of psychotomimetic agents. Ann. N. Y. Acad. Sci. 66, 418–434 (1957).
pubmed: 13425232
doi: 10.1111/j.1749-6632.1957.tb40738.x
Stanislav, G. Beyond the Brain: Birth, Death, and Transcendence in Psychotherapy (State University of New York Press, 1985).
Smith, C. M. Some reflections on the possible therapeutic effects of the hallucinogens. With special reference to alcoholism. Q. J. Stud. Alcohol 20, 292–301 (1959).
pubmed: 13668045
doi: 10.15288/qjsa.1959.20.292
Smart, R. G., Storm, T., Baker, E. F. W. & Solursh, L. A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. Q. J. Stud. Alcohol 27, 469–482 (1966).
pubmed: 5970697
doi: 10.15288/qjsa.1966.27.469
Bishop, M. G. The Discovery Of Love: A Psychedelic Experience With LSD-25 (Torquil, 1963).
Abramson, H. A. LSD in psychotherapy and alcoholism. Am. J. Psychother. 20, 415–438 (1966).
pubmed: 5337647
doi: 10.1176/appi.psychotherapy.1966.20.3.415
Parley, K. A. Y. Supporting the patient. AJN Am. J. Nurs. 64, 80–82 (1964).
Kast, E. Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr. Q. 41, 646–657 (1967).
pubmed: 4169685
doi: 10.1007/BF01575629
MacLean, J. R., MacDonald, D. C., Byrne, U. P. & Hubbard, A. M. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q. J. Stud. Alcohol 22, 34–45 (1961).
pubmed: 13764952
doi: 10.15288/qjsa.1961.22.034
Pahnke, W. N., Kurland, A. A., Goodman, L. E. & Richards, W. A. LSD-assisted psychotherapy with terminal cancer patients. Curr. Psychiatr. Ther. 9, 144–152 (1969).
pubmed: 5348915
Cohen, S. Lysergic acid diethylamide: side effects and complications. J. Nerv. Ment. Dis. 130, 30–40 (1960).
pubmed: 13811003
doi: 10.1097/00005053-196001000-00005
Johnstad, P. G. A dangerous method? Psychedelic therapy at Modum Bad, Norway, 1961-76. Hist. Psychiatry 31, 217–226 (2020).
pubmed: 31928087
doi: 10.1177/0957154X19894537
Richards, W. A. Psychedelic psychotherapy: insights from 25 years of research. J. Humanist. Psychol. 57, 323–337 (2017).
doi: 10.1177/0022167816670996
Maggio, C., Fischer, F., Modlin, N. & Rucker, J. Psychoanalytic formulations in psychedelic therapy for Treatment Resistant Depression (TRD). J. Psychol. Psychother. 13, 451 (2023).
Johnson, M. W., Richards, W. A. & Griffiths, R. R. Human hallucinogen research: guidelines for safety. J. Psychopharmacol. 22, 603–620 (2008).
pubmed: 18593734
pmcid: 3056407
doi: 10.1177/0269881108093587
Grof, C. & Grof, S. Spiritual emergency: the understanding and treatment of transpersonal crises. Int. J. Transpers. Stud. 36, 30–43 (2017).
doi: 10.24972/ijts.2017.36.2.30
Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).
pubmed: 36322843
doi: 10.1056/NEJMoa2206443
Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843–853 (2023).
pubmed: 37651119
pmcid: 10472268
doi: 10.1001/jama.2023.14530
Mithoefer, M. C. A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder https://maps.org/mdma/mdma-resources/treatment-manual-mdma-assisted-psychotherapy-for-ptsd/ (2022).
Bogenschutz, M. P. et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289–299 (2015).
pubmed: 25586396
doi: 10.1177/0269881114565144
Johnson, M. W. Classic psychedelics in addiction treatment: the case for psilocybin in tobacco smoking cessation. Curr. Top. Behav. Neurosci. 56, 213–227 (2022).
pubmed: 35704271
doi: 10.1007/7854_2022_327
Guss J., Krause R. & Sloshower, J. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame). (2020).
Payne, J. E., Chambers, R. & Liknaitzky, P. Combining psychedelic and mindfulness interventions: synergies to inform clinical practice. ACS Pharmacol. Transl. Sci. 4, 416–423 (2021).
pubmed: 33860171
pmcid: 8033772
doi: 10.1021/acsptsci.1c00034
Yaden, D. B. et al. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front. Psychol. 13, 873279 (2022).
pubmed: 35677124
pmcid: 9169963
doi: 10.3389/fpsyg.2022.873279
Brennan, W. & Belser, A. B. Models of psychedelic-assisted psychotherapy: a contemporary assessment and an introduction to embark, a transdiagnostic, trans-drug model. Front. Psychol. 13, 866018 (2022).
pubmed: 35719571
pmcid: 9201428
doi: 10.3389/fpsyg.2022.866018
Studerus, E., Kometer, M., Hasler, F. & Vollenweider, F. X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J. Psychopharmacol. 25, 1434–1452 (2011).
pubmed: 20855349
doi: 10.1177/0269881110382466
Modlin, N. L. et al. Optimizing outcomes in psilocybin therapy: considerations in participant evaluation and preparation. J. Affect Disord. 326, 18–25 (2023).
pubmed: 36707036
doi: 10.1016/j.jad.2023.01.077
Greń, J. et al. Call for evidence-based psychedelic integration. Exp. Clin. Psychopharmacol. 32, 129–135 (2024).
pubmed: 38010760
doi: 10.1037/pha0000684
de Vos, C. M. H., Mason, N. L. & Kuypers, K. P. C. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front. Psychiatry 12, 724606 (2021).
pubmed: 34566723
pmcid: 8461007
doi: 10.3389/fpsyt.2021.724606
Wall, M. B. et al. Neuroimaging in psychedelic drug development: past, present, and future. Mol. Psychiatry 28, 3573–3580 (2023).
pubmed: 37759038
pmcid: 10730398
doi: 10.1038/s41380-023-02271-0
Goodwin, G. M., Malievskaia, E., Fonzo, G. A. & Nemeroff, C. B. Must psilocybin always “assist psychotherapy”? Am. J. Psychiatry 181, 20–25 (2024).
pubmed: 37434509
doi: 10.1176/appi.ajp.20221043
Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T. & Monson, C. M. Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-methylenedioxymethamphetamine (MDMA): a case example. J. Psychoact. Drugs 51, 166–173 (2019).
doi: 10.1080/02791072.2019.1589028
Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C. & Grof, S. The experimental use of psychedelic (LSD) psychotherapy. JAMA 212, 1856–1863 (1970).
pubmed: 5467681
doi: 10.1001/jama.1970.03170240060010
Sherwood, J. N., Stolaroff, M. J. & Harman, W. W. The psychedelic experience-a new concept in psychotherapy. J. Neuropsychiatry 4, 69–80 (1962).
Sloshower, J. et al. Psilocybin-assisted therapy of major depressive disorder using acceptance and commitment therapy as a therapeutic frame. J. Context. Behav. Sci. 15, 12–19 (2020).
doi: 10.1016/j.jcbs.2019.11.002
Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165–1180 (2016).
pubmed: 27909164
pmcid: 5367551
doi: 10.1177/0269881116675512
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. & Griffiths, R. R. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28, 983–992 (2014).
pubmed: 25213996
pmcid: 4286320
doi: 10.1177/0269881114548296
Stauffer, C. S., Anderson, B. T., Ortigo, K. M. & Woolley, J. Psilocybin-assisted group therapy and attachment: observed reduction in attachment anxiety and influences of attachment insecurity on the psilocybin experience. ACS Pharmacol. Transl. Sci. 4, 526–532 (2020).
pubmed: 33860182
pmcid: 8033604
doi: 10.1021/acsptsci.0c00169
Carhart-Harris, R. L. et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3, 619–627 (2016).
pubmed: 27210031
doi: 10.1016/S2215-0366(16)30065-7
Doss, M. K. et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl. Psychiatry 11, 574 (2021).
pubmed: 34750350
pmcid: 8575795
doi: 10.1038/s41398-021-01706-y
Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57–68 (2015).
pubmed: 25389218
doi: 10.1177/0269881114555249
Palhano-Fontes, F. et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol. Med. 49, 655–663 (2019).
pubmed: 29903051
pmcid: 6378413
doi: 10.1017/S0033291718001356
Mithoefer, M. C. et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236, 2735–2745 (2019).
pubmed: 31065731
pmcid: 6695343
doi: 10.1007/s00213-019-05249-5
Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021).
pubmed: 33972795
pmcid: 8205851
doi: 10.1038/s41591-021-01336-3